Common Arthritis Drugs Reduce Systemic Sjögren's Disease Activity in 24 Weeks

Why It Matters

The finding provides the first evidence that inexpensive, widely available arthritis drugs can control systemic Sjögren's activity, opening a scalable treatment option for a disease that currently lacks disease‑modifying therapy.

Key Takeaways

• Leflunomide‑hydroxychloroquine cut ESSDAI scores by >4 points vs placebo
• Trial enrolled 46 Sjögren’s patients across 12 Dutch centers
• First DMARD regimen showing efficacy without background immunosuppression
• Treatment was oral, affordable, and well tolerated overall
• Results suggest immune‑pathway suppression may lower lymphoma risk

Pulse Analysis

Sjögren's syndrome affects roughly half a percent of the population, predominantly women, and while dry eyes and mouth are managed with lubricants, systemic involvement of skin, lungs, kidneys, and heightened lymphoma risk has long lacked a disease‑modifying therapy. The absence of approved agents forces clinicians to rely on symptomatic care, creating a therapeutic void that hampers patient quality of life and drives costly downstream complications. Understanding the autoimmune pathways—B‑cell hyperactivity, interferon signaling, and chemokine cascades—has been essential for identifying repurposing opportunities.

The RepurpSS‑II trial, a double‑blind, placebo‑controlled phase 2b study, randomized 46 patients to receive leflunomide plus hydroxychloroquine or placebo for 24 weeks. The combination produced a mean ESSDAI reduction exceeding four points, a clinically meaningful shift that mirrors earlier proof‑of‑concept data. Importantly, the trial excluded any background immunosuppressants, isolating the DMARDs’ impact and confirming safety: gastrointestinal upset was the most frequent adverse event, and a solitary myocardial infarction was judged unrelated. Oral administration and low cost position these drugs as a pragmatic alternative to biologics, especially for health systems constrained by budget.

Beyond immediate clinical benefits, the study reinforces the concept that targeting multiple immune axes can blunt the chronic inflammation driving Sjögren's systemic manifestations and potentially lower lymphoma incidence. The affordability and global availability of leflunomide and hydroxychloroquine make the regimen attractive for low‑resource settings, where access to specialty biologics is limited. Future larger trials will need to assess long‑term outcomes, symptom domains such as fatigue, and applicability to milder disease phenotypes, but the current data already signal a shift toward repurposed DMARDs as a viable, scalable therapeutic class for Sjögren's syndrome.